ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 75

Ferritin:ESR, A Predictor of MAS?

Miriah Gillispie1, Marietta DeGuzman2, Mark Gorelik3 and Tiphanie Vogel4,5, 1Pediatrics, Department of IAR, Baylor College of Medicine, Houston, TX, 2Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 3Baylor College of Medicine, San Antonio, TX, 4Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, 5Center for Human Immunobiology, Texas Children's Hospital, Houston, TX

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: Systemic JIA and macrophage activation syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Thursday, May 18, 2017

Title: Clinical and Therapeutic Poster Session

Session Type: Abstract Submissions

Session Time: 5:30PM-7:00PM

Background/Purpose:

Systemic onset juvenile idiopathic arthritis (SoJIA) is a rare autoinflammatory disorder comprising only 10% of JIA. Macrophage activation syndrome (MAS), an excessive and uncontrolled immune expansion, can develop within the setting of SoJIA. MAS is often overt but can be subclinical in up to 40% of patients. Early recognition of MAS is imperative, as the mortality rate despite treatment is high. Unfortunately, there is no pathognomonic finding for MAS, which can lead to delayed recognition. Use of the ratio between ferritin and erythrocyte sedimentation rate (ESR) has been reported to discern between flares of SoJIA, other febrile illnesses, and MAS.  The purpose of our project was to determine if utilization of the ferritin:ESR ratio at the onset of SoJIA could predict our patients with SoJIA who developed MAS.

Methods:

A single center, retrospective chart review of SoJIA patients was performed and data were extracted at the patientsÕ initial presentation.  Patients presenting initially to an outlying facility with incomplete records were excluded. The 2016 Ravelli criteria were used to identify those patients with MAS. SoJIA patients with and without MAS were compared using descriptive statistics. Binary logistic regression analysis was performed to identify predictors of MAS.

Results:

Eight of 30 patients met criteria for MAS during initial presentation. Laboratory analysis can be found in Table 1. Patients with MAS had significantly higher AST, CRP, and triglyceride levels with lower fibrinogen levels. Binary logistic regression did not indicate any significant predictive variables for MAS.

Table 1: Laboratory Analysis

SoJIA

(median [IQR])

SoJIA+MAS (median [IQR])

p

AST (U/L)

40 [36,50]

67.5 [56,79]

0.048

CRP (mg/dL)

16.1 [11.9,24]

35 [33.7,36.4]

0.004

Fibrinogen (mg/dL)

558 [502,652]

380 [227,533]

0.039

Triglycerides (mg/dL)

93 [79.5,134]

123 [88,158]

0.032

Ferritin (ng/mL)

2898 [2165,4360]

8875 [4650,13100]

0.069

ANC (103/uL)

18.5 [10.1,22.8]

12.5 [0.6,14.4]

0.524

ESR (mm/hr)

80 [46,86]

60 [58,62]

0.709

Hemoglobin (g/dL)

10.4 [8.8,10.7]

9.9 [8.5,11.2]

0.701

Platelets (103/uL)

422 [399,514]

321 [177,465]

0.532

WBC (103/uL)

21.7 [16.1,25.9]

15 [13.3,16.87]

0.077

Ferritin:ESR

33.4 [28.4,50.4]

146 [80,211]

0.135

NK cell function

0.5 [0,3.4]

1.05 [0.1,2]

1

soluble IL-2R

1555 [1372,3844]

1990 [1859,2121]

0.133

Conclusion:

No single laboratory value, including the ferritin to ESR ratio, was associated with the development of MAS at the initial presentation of SoJIA. These findings highlight the need for a comprehensive clinical and laboratory evaluation in all SoJIA patients to identify MAS.


Disclosure: M. Gillispie, None; M. DeGuzman, None; M. Gorelik, None; T. Vogel, None.

To cite this abstract in AMA style:

Gillispie M, DeGuzman M, Gorelik M, Vogel T. Ferritin:ESR, A Predictor of MAS? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/ferritinesr-a-predictor-of-mas/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ferritinesr-a-predictor-of-mas/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology